Furthermore, we studied the effect of several Bcl-2 family inhibitors (BH3 mimetics) that have been developed to treat in particular hemato-oncology patients as potential therapeutic targets for the treatment of both autoimmune diseases. This evidence concerns the gene BCL2 and autoimmune disease.